# Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

> **NCT03992729** · — · RECRUITING · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 200 (estimated)

## Conditions studied

- Pregnancy Related

## Interventions

- **DRUG:** Pregnant women exposed to tildrakizumab
- **DRUG:** Pregnant women not exposed to tildrakizumab

## Key facts

- **NCT ID:** NCT03992729
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-29
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992729, "Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03992729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*